Reason for request
New indication
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of ENHERTU (trastuzumab deruxtecan) is substantial “as monotherapy in adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received at least two prior trastuzumab-based treatment lines”.
|
| Insufficient |
Considering all these elements, the Committee deems that the clinical benefit of ENHERTU (trastuzumab deruxtecan) is insufficient in the other situations of the MA indication extension - i.e. as second-line therapy - to justify public funding cover.
|
Clinical Added Value
| minor |
Considering:
- demonstration of a superiority in the phase 2 DESTINY-Gastric01 study of T-DXd treatment compared to treatment of the physician’s choice (TPC) in terms of:
- ORR (primary endpoint) with a differential of + 37.0% (CI95% = [41.9; 60.5] in the T-DXd group and CI95% = [6.4; 26.2] in the TPC group; p < 0.0001) in favour of T-DXd,
- OS (ranked secondary endpoint) with a differential of + 4.1 months (HR = 0.59, CI95%: [0.39; 0.88]; p=0.0097) in favour of T-DXd,
- the inadequately met medical need insofar as the efficacy of LONSURF (trifluridine / tipiracil) is limited with short median PFS and OS durations;
and despite:
- the lack of demonstration of any superiority of T-DXd treatment compared to the LONSURF comparator (trifluridine / tipiracil);
- questions concerning the transposability of the results of the DESTINY-Gastric01 study, conducted in Asia only;
- an excess haematotoxicity (neutropenia, anaemia, leukopenia, lymphopenia and thrombocytopenia);
- the risk of diffuse interstitial lung disease/pneumonitis, identified as an important risk in the RMP;
- the absence of a demonstrated impact on quality of life (exploratory endpoint).
the Committee deems that ENHERTU (trastuzumab deruxtecan) provides a minor clinical added value (CAV IV) in the current care pathway as third or later-line treatment, which includes LONSURF (trifluridine / tipiracil).
|
| Not applicable |
|
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
m0HdRSqwQebYhEYS